Contaminants of dinitrochlorobenzene

Michael Wilkerson, J. K. Wilkin, R. G. Smith

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

DNCB (2,4-dinitrochlorobenzene) is used in the treatment of alopecia areata, recalcitrant verrucae, and for evaluating immunocompromised patients. Currently, there is no pharmaceutical grade of DNCB available for clinical use. Recently, no nitrochlorobenzene contamination was found with the use of positive ion detection gas chromatography-mass spectrometry. We examined six commercial sources of DNCB, with the use of negative ion detection gas chromatography-mass spectrometry, for volatile impurities such as nitrochlorobenzene which might remain from the manufacturing process. The use of negative ion detection increases the sensitivity of this technic to benzene rings substituted with electron withdrawing groups like the nitrochlorobenzenes. We found that all sources of DNCB contain various combinations of nitrochlorobenzene, dinitrobenzene, nitrodichlorobenzene, and other isomers of DNCB. Nitrochlorobenzene has been shown to be mutagenic in the Ames test and carcinogenic in animal studies. The presence of nitrochlorobenzene and other contaminants in commercial grades of DNCB raises questions about the continued clinical application of this agent.

Original languageEnglish (US)
Pages (from-to)554-557
Number of pages4
JournalJournal of the American Academy of Dermatology
Volume9
Issue number4
StatePublished - 1983
Externally publishedYes

Fingerprint

Dinitrochlorobenzene
Ions
Gas Chromatography-Mass Spectrometry
Dinitrobenzenes
Alopecia Areata
Warts
Immunocompromised Host
Benzene
Electrons
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Dermatology

Cite this

Contaminants of dinitrochlorobenzene. / Wilkerson, Michael; Wilkin, J. K.; Smith, R. G.

In: Journal of the American Academy of Dermatology, Vol. 9, No. 4, 1983, p. 554-557.

Research output: Contribution to journalArticle

Wilkerson, M, Wilkin, JK & Smith, RG 1983, 'Contaminants of dinitrochlorobenzene', Journal of the American Academy of Dermatology, vol. 9, no. 4, pp. 554-557.
Wilkerson, Michael ; Wilkin, J. K. ; Smith, R. G. / Contaminants of dinitrochlorobenzene. In: Journal of the American Academy of Dermatology. 1983 ; Vol. 9, No. 4. pp. 554-557.
@article{56f1d7616dd042338e50be0f28ad1bd0,
title = "Contaminants of dinitrochlorobenzene",
abstract = "DNCB (2,4-dinitrochlorobenzene) is used in the treatment of alopecia areata, recalcitrant verrucae, and for evaluating immunocompromised patients. Currently, there is no pharmaceutical grade of DNCB available for clinical use. Recently, no nitrochlorobenzene contamination was found with the use of positive ion detection gas chromatography-mass spectrometry. We examined six commercial sources of DNCB, with the use of negative ion detection gas chromatography-mass spectrometry, for volatile impurities such as nitrochlorobenzene which might remain from the manufacturing process. The use of negative ion detection increases the sensitivity of this technic to benzene rings substituted with electron withdrawing groups like the nitrochlorobenzenes. We found that all sources of DNCB contain various combinations of nitrochlorobenzene, dinitrobenzene, nitrodichlorobenzene, and other isomers of DNCB. Nitrochlorobenzene has been shown to be mutagenic in the Ames test and carcinogenic in animal studies. The presence of nitrochlorobenzene and other contaminants in commercial grades of DNCB raises questions about the continued clinical application of this agent.",
author = "Michael Wilkerson and Wilkin, {J. K.} and Smith, {R. G.}",
year = "1983",
language = "English (US)",
volume = "9",
pages = "554--557",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Contaminants of dinitrochlorobenzene

AU - Wilkerson, Michael

AU - Wilkin, J. K.

AU - Smith, R. G.

PY - 1983

Y1 - 1983

N2 - DNCB (2,4-dinitrochlorobenzene) is used in the treatment of alopecia areata, recalcitrant verrucae, and for evaluating immunocompromised patients. Currently, there is no pharmaceutical grade of DNCB available for clinical use. Recently, no nitrochlorobenzene contamination was found with the use of positive ion detection gas chromatography-mass spectrometry. We examined six commercial sources of DNCB, with the use of negative ion detection gas chromatography-mass spectrometry, for volatile impurities such as nitrochlorobenzene which might remain from the manufacturing process. The use of negative ion detection increases the sensitivity of this technic to benzene rings substituted with electron withdrawing groups like the nitrochlorobenzenes. We found that all sources of DNCB contain various combinations of nitrochlorobenzene, dinitrobenzene, nitrodichlorobenzene, and other isomers of DNCB. Nitrochlorobenzene has been shown to be mutagenic in the Ames test and carcinogenic in animal studies. The presence of nitrochlorobenzene and other contaminants in commercial grades of DNCB raises questions about the continued clinical application of this agent.

AB - DNCB (2,4-dinitrochlorobenzene) is used in the treatment of alopecia areata, recalcitrant verrucae, and for evaluating immunocompromised patients. Currently, there is no pharmaceutical grade of DNCB available for clinical use. Recently, no nitrochlorobenzene contamination was found with the use of positive ion detection gas chromatography-mass spectrometry. We examined six commercial sources of DNCB, with the use of negative ion detection gas chromatography-mass spectrometry, for volatile impurities such as nitrochlorobenzene which might remain from the manufacturing process. The use of negative ion detection increases the sensitivity of this technic to benzene rings substituted with electron withdrawing groups like the nitrochlorobenzenes. We found that all sources of DNCB contain various combinations of nitrochlorobenzene, dinitrobenzene, nitrodichlorobenzene, and other isomers of DNCB. Nitrochlorobenzene has been shown to be mutagenic in the Ames test and carcinogenic in animal studies. The presence of nitrochlorobenzene and other contaminants in commercial grades of DNCB raises questions about the continued clinical application of this agent.

UR - http://www.scopus.com/inward/record.url?scp=0020543137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020543137&partnerID=8YFLogxK

M3 - Article

C2 - 6630616

AN - SCOPUS:0020543137

VL - 9

SP - 554

EP - 557

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 4

ER -